Covid 19 Profit (x9)

Last Friday, the Eli Lilly & Co. (LLY) partner in the fight against Covid 19, AbCellera Biologics Inc., announced that the two medical companies have expanded their collaboration to go beyond the effort to battle the virus.  AbCellera is unique in their scientific minds, method, and equipment that can be marshaled to discover useful antibodies as a powerful weapon against disease.  But now, not only will Eli Lilly & Co. (LLY) be advancing towards a Covid 19 product, there is a deal for possibly 9 medicines to counter different medical issues that could prove equally lucrative.  Through trying a novel antibody identification approach, Eli Lilly & Co. (LLY) believes it has stumbled upon a wealth of opportunity that can be the mother load of future profits.

Daniel Skovronsky, M.D., Ph.D., Lilly's chief scientific officer and president of Lilly Research Laboratories, stated, "AbCellera's capabilities and team are extremely impressive and we are proud of the progress we've made together thus far."

Paul Wharton

Special thanks to Eli Lilly & Co. (LLY) for inventing the fuel of my mind